Supplemental Table 1 Biodistribution and organ dosimetry in a pig after 11 C-metformin administration at baseline condition and during metformin infusion.
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Supplemental Materials and Methods

Chemicals
Ammonium dihydrogenphosphate, phosphoric acid, metformin hydrochloride, cimetidine, quinine, cisplatin, tetrabutylammonium hydrogen phosphate and acetone were obtained from Sigma-Aldrich Ltd. and used as received. 1-methylbiguanide (as hydrochloride salt) was from LGC Standards. Water (sterile) and aqueous NaOH (3 M; sterile) were prepared by the pharmacy at Aarhus University Hospital.
Radiochemistry
Cyclotron-produced 11CO2 or 11CH4 was converted to 11CH3I and further to 11CH3OTf and then directed to the reaction vial containing the precursor in acetone and sodium hydroxide as a supporting base. After heating the reaction mixture for 5 min at 70 degrees, the crude product is diluted with 1 ml water and purified by reverse phase HPLC on a Luna SCX (10 µm, 10x250 mm) (Phenomenex) column with aqueous (NH4)2HPO4 (100 mM)
as mobile phase (flow 15 ml/min; λ = 232 nm). The fraction from the chromatographic separation corresponding to 11C-metformin was collected (from ca. 6.5 -8 min) and passed over a sterile filter (Cathivex-GS 0,22 µm (Millipore)) into the final sterile product vial.
The radiochemical purity of the synthesized 11C-metformin was determined by analytical HPLC using an Ultimate® 3000 system (Dionex) (λ= 232 nm)
connected to a GabiStar radio-detector (Nuclear Interface). The chromatographic column was a Luna 5µ SCX 100A (150 x 4.6 mm) (Phenomenex) with aqueous (NH4)2HPO4 (100 mM; adjusted to pH 5 with H3PO4) as eluent (isocratic, 2.5 mL/min). The chromatographic data were analyzed using Chromeleon software (Dionex) (version 6.80). The identity of 11C-metformin (retention time: 3.4 min) was confirmed by co-injection of reference material. Additional chromatographic conditions were used for the identification of 11 C-metformin: Luna C18(2) 150x4.6 mm (Phenomenex) eluted with 30% acetonitrile 70% 10 mM sodium octanesulfonate (pH adjusted to 3 with sulfuric acid). On this HPLC system, 11C-metformin had a retention time of 5 min.
Supplemental Experimental Procedures
Animal studies
The studies were performed according to the Danish Animal 
Autoradiography studies
Lewis rats (250 -285 gram, male) were injected intravenously in a tail vein with 10-20 MBq 11 C-metformin under isoflurane anaesthesia. Two minutes after tracer injection rats were killed by decapitation and kidney and liver tissue were rapidly removed, cooled to -40 degrees in isopentane. Ten micron thick slices were cut, shortly dried and transferred to a metal cassette and exposed to a phosphor imaging plate for 1 hour. Subsequently the plates were read using a FujiBAS ImageReader. To estimate the pharmacokinetics of 11 C-metformin in the renal cortex we used a simple 1-tissue compartment model with K1 as rate constant for the transport from plasma into tissue and k2 as tissue clearance parameter. The PET-derived distribution volume was calculated as the ratio K1/k2.
MicroPET experiments in rats
Alternatively, the distribution volume in renal cortex could be estimated as the ratio of the area-under-the-curve (AUC) for renal cortex to that of plasma, each calculated at presumed steady-state 60 min post-injection.
From the CT scan, we derived the renal cortex volume Vcortex. and a dilution of the urine, respectively. All tubes were counted twice, first for 11 C-metformin and 6 hours later for 51 Cr-EDTA.
Urine clearance = U x V / P Where U is the activity excreted in the urine collection time interval, V is the urine volume and P is the activity in the plasma sample.
Biodistribution, metabolites and protein binding
To examine the arterial input of 11 C-metformin blood was sampled (0. wall and urinary bladder contents) and were included as individual source organs. The salivary glands could be identified, but their contribution was small and could be ignored in the calculations. The total liver radioactivity was estimated as the radioactivity concentration in a liver VOI multiplied by the liver volume. In the similar way, the total radioactivity was estimated in kidney and heart wall. The urinary bladder contents were measured using urine samples. For each source organ, the time course of the non-decaycorrected total radioactivity was generated. Data were extrapolated from pig 
